Clinical Trials
60 trialsRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
RICER
Hackensack Meridian Health
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
LOC-R01
Institut Curie
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Pola-ZR2P in Previously Untreated DLBCL
Navy General Hospital, Beijing
REPIFIR
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Ruijin Hospital
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Mayo Clinic
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
Seoul National University Hospital
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
Ruijin Hospital
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
M.D. Anderson Cancer Center
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Navy General Hospital, Beijing
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
RV-NHL-PI351
IRCCS San Raffaele
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
Peking Union Medical College Hospital
ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL
Zhejiang Cancer Hospital
Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma
Ruijin Hospital
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
Ruijin Hospital
The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years
Ruijin Hospital
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Relyage
Centre Hospitalier Universitaire, Amiens
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
Second Affiliated Hospital of Soochow University
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Huazhong University of Science and Technology
ZR2-CHOP
The First Affiliated Hospital with Nanjing Medical University
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Washington University School of Medicine
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
REMARC
The Lymphoma Academic Research Organisation
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
The Lymphoma Academic Research Organisation
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
Ruijin Hospital
Biomarker Guided Treatment in DLBCL
Ruijin Hospital
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
Nanfang Hospital, Southern Medical University
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
M.D. Anderson Cancer Center
LEGEND
Royal Marsden NHS Foundation Trust
Lenalidomide Based Immunotherapy in the Treatment of DLBCL
Ruijin Hospital